A recent snapshot of China’s medical market shows a surge of home‑grown, cutting‑edge medicines that are now competing with the world’s best. A new white paper released in Shanghai reveals that between 2018 and 2025, China contributed almost 40 % of all innovative drugs entering clinical trials worldwide, climbing to 47.4 % by 2025. In plain terms, for every two new drugs tested globally, one comes from China. The momentum is reflected in the performance of the Medical Innovation ETF (ticker 516820), which trades at 0.32 yuan. Its intraday turnover sits at 0.3 % with a daily volume of about 5.3 million yuan, while the average daily volume over the past year has been roughly 50 million yuan, indicating steady investor interest. Chinese biotech firms are also making headlines at the 2026 ASCO conference. Kelun Bio reported that its experimental therapy sac‑TMT, combined with pembrolizumab, significantly extended progression‑free survival for patients with advanced lung cancer. Baili Tianheng’s iza‑bren showed both overall‑survival and progression‑free‑survival gains in esophageal cancer, and BeiGene’s CDK4 inhibitor achieved high response and disease‑control rates. These results suggest Chinese drugs are moving from domestic labs into global efficacy trials, positioning China as a new powerhouse in pharmaceutical innovation.
Read more